Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose TBI/G-CSF-combined cytarabine in single cord blood transplantation for elderly patients with non-remission myeloid malignancies

Allogeneic hematopoietic cell transplantation (HCT) is the only potential curative therapy for patients with non-remission myeloid malignancies [1-3]. Cord blood transplantation (CBT) is an acceptable alternative donor source for patients without human leukocyte antigen (HLA)-matched related or unrelated donors in need of allogeneic HCT [4-9]. Owing to its rapid availability, CBT can enable patients with non-remission myeloid malignancies to perform allogeneic HCT at the optimal time. In addition, because recipient and donor ages are usually similar and the prevalence of various comorbidities increases with age, it is difficult to find suitable HLA-matched sibling donors for elderly patients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research